The liver is an organ with strong regenerative capacity, yet primary hepatocytes have a low amplification potential in vitro, a major limitation for the cell-based therapy of liver disorders and for ex vivo biological screens. Induced pluripotent stem cells (iPSC) may help to circumvent this obstacle, but often harbor genetic and epigenetic abnormalities limiting their potential. Here, we describe the pharmacological induction of proliferative human hepatic progenitor cells (HPC) through a cocktail of growth factors and small molecules mimicking the signaling events involved in liver regeneration. Human HPC from healthy donors and pediatric patients proliferated vigorously while maintaining their genomic stability and could be re-differentiated in vitro into metabolically competent cells that supported the replication of hepatitis B and Delta viruses. Re-differentiation efficiency was boosted by 3D culture. Finally, transcriptome analysis showed that HPC were more closely related to mature hepatocytes than iPSC-derived hepatocyte-like cells were. Conclusion: HPC induction holds promises for a variety of applications such as ex vivo disease modeling, personalized drug testing or metabolic studies and development of a bio-artificial liver.

Pharmacological induction of a progenitor state for the efficient expansion of primary human hepatocytes / C. Unzu, E. Planet, N. Brandenberg, F. Fusil, M. Cassano, J. Perez-Vargas, M. Friedli, F. Cosset, M.P. Lutolf, B.E. Wildhaber, D. Trono. - In: HEPATOLOGY. - ISSN 0270-9139. - 69:5(2019 May), pp. 2214-2231. [10.1002/hep.30425]

Pharmacological induction of a progenitor state for the efficient expansion of primary human hepatocytes

M. Cassano;
2019-05

Abstract

The liver is an organ with strong regenerative capacity, yet primary hepatocytes have a low amplification potential in vitro, a major limitation for the cell-based therapy of liver disorders and for ex vivo biological screens. Induced pluripotent stem cells (iPSC) may help to circumvent this obstacle, but often harbor genetic and epigenetic abnormalities limiting their potential. Here, we describe the pharmacological induction of proliferative human hepatic progenitor cells (HPC) through a cocktail of growth factors and small molecules mimicking the signaling events involved in liver regeneration. Human HPC from healthy donors and pediatric patients proliferated vigorously while maintaining their genomic stability and could be re-differentiated in vitro into metabolically competent cells that supported the replication of hepatitis B and Delta viruses. Re-differentiation efficiency was boosted by 3D culture. Finally, transcriptome analysis showed that HPC were more closely related to mature hepatocytes than iPSC-derived hepatocyte-like cells were. Conclusion: HPC induction holds promises for a variety of applications such as ex vivo disease modeling, personalized drug testing or metabolic studies and development of a bio-artificial liver.
ex-vivo liver disease modeling; human hepatocytes; proliferation
Settore BIO/17 - Istologia
14-dic-2018
Article (author)
File in questo prodotto:
File Dimensione Formato  
Unzu_et_al-2019-Hepatology.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 1.77 MB
Formato Adobe PDF
1.77 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/618930
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 12
social impact